Table 1. Comparison of primary demographic data and known prognostic factors of overall survival after thoracic metastasectomy between groups based on mutational status.
| Wild type | mKRAS | mBRAF | P-value | |
|---|---|---|---|---|
|
n |
68 (37.8%) |
93 (51.7%) |
19 (10.6%) |
— |
| Age>60 years |
50 (73.5%) |
62 (66.7%) |
13 (68.4%) |
0.64 |
| WHO PS |
— |
— |
— |
0.83 |
| 0 (n=132) | 49 (72.1%) | 68 (73.1%) | 15 (78.9%) | — |
| 1 (n=48) |
19 (29.9%) |
25 (26.9%) |
4 (11.1%) |
— |
| CCI |
— |
— |
— |
<0.0001 |
| 0 (n=19) | 13 (19.1%) | 6 (6.5%) | 0 | — |
| 1 (n=68) | 49 (72.1%) | 16 (17.2%) | 3 (15.8%) | — |
| 2 (n=46) | 6 (8.8%) | 37 (39.8%) | 3 (15.8%) | — |
| 3 (n=47) |
0 |
34 (36.6%) |
13 (68.4%) |
— |
| Gender |
— |
— |
— |
0.34 |
| Male (n=112) | 44 (64.7%) | 56 (60.2%) | 12 (63.2%) | — |
| Female (n=68) |
24 (35.3%) |
43 (39.8%) |
7 (26.8%) |
— |
| pT stage of the primary CRC |
— |
— |
— |
0.001 |
| pT1 (n=23) | 12 (17.6%) | 11 (11.8%) | 0 (0%) | — |
| pT2 (n=23) | 12 (17.6%) | 10 (10.8%) | 1 (5.3%) | — |
| pT3 (n=98) | 39 (57.4%) | 51 (54.8%) | 8 (42.1%) | — |
| pT4 (n=36) |
5 (7.4%) |
21 (22.6%) |
10 (52.6%) |
— |
| pN stage of the primary CRC |
— |
— |
— |
0.05 |
| pN0 (n=93) | 32 (47.1%) | 55 (59.1%) | 6 (31.6%) | — |
| pN+ (n=87) |
36 (52.9%) |
38 (40.9%) |
13 (68.4%) |
— |
| Neo-adjuvant chemotherapy before CRC |
— |
— |
— |
0.12 |
| Yes (n=93) | 38 (55.9%) | 42 (45.2%) | 13 (68.4%) | — |
| No (n=87) |
30 (44.1%) |
51 (54.8%) |
6 (31.6%) |
— |
| Adjuvant chemotherapy after CRC |
— |
— |
— |
0.02 |
| Yes (n=106) | 37 (54.4%) | 52 (55.9%) | 17 (89.5%) | — |
| No (n=74) |
31 (45.6%) |
41(44.1%) |
2 (10.5%) |
— |
| Age at time of metastasectomy |
62.29 (±9.82) |
64.74 (±8.59) |
64.42 (±10.2) |
0.24 |
| Thoracic LNI |
— |
— |
— |
<0.0001 |
| Yes (n=58) | 0 (0%) | 40 (43%) | 18 (94.7%) | — |
| No (n=122) |
68 (100%) |
53 (57%) |
1 (5.3%) |
— |
| >1 thoracic metastases (n=88) |
20 (29.4%) |
55 (59.1%) |
13 (68.4%) |
<0.0001 |
| Liver metastases (n=27) |
6 (8.8%) |
15 (16.1%) |
6 (31.6%) |
0.04 |
| Pre-CEA⩾5 (n=71) |
32 (47.1%) |
31 (33.3%) |
8 (42.1%) |
0.21 |
| DFS<24 months | 16 (23.5%) | 33 (35.5%) | 9 (47.4%) | 0.09 |
Abbreviations: CCI=Charlson comorbidity index; CRC=colorectal cancer; DFS=disease-free survival (defined as the time elapsed between colorectal tumour surgery and the first appearance of metastases); LNI=lymph node involvement; mBRAF=mutant BRAF; mKRAS=mutant KRAS; pre-CEA=preoperative carcinoembryonic antigen; WHO PS=World Health Organization Performance Status. Bold values indicate significant P-values.